<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449771</url>
  </required_header>
  <id_info>
    <org_study_id>9878</org_study_id>
    <nct_id>NCT03449771</nct_id>
  </id_info>
  <brief_title>PrEP and Consumptions</brief_title>
  <acronym>PrEP</acronym>
  <official_title>Screening of Psychoactive Substances Use and Anxio-depressive Disorders in Consultation for HIV Pre-exposure Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV pre-exposure prophylaxis (PrEP) with Truvada®, a combination of two antiretrovirals
      (tenofovir &amp; emtricitabine) is a prevention strategy for HIV-negative people at high risk of
      acquiring HIV. PrEP has thus been integrated as a new tool to significantly reduce the risk
      of HIV infection, especially among men who have sex with men (MSM). Since its introduction,
      an increase in sexually transmitted infections (STIs) has been observed, particularly in
      relation to the use of psychoactive substances in a sexual context (Chemsex).

      In this context, the description and evaluation of these practices seem necessary, as well as
      the impact on the risk of addiction and mental health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, multi-center pilot study, including all subjects aged 18 years or older
      presenting in consultation for a PrEP renewal.

      The newsletter and a self-questionnaire will be systematically given in the waiting room to
      any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST
      questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital
      Anxiety and Depression). scale). After consent, the answers will be discussed with the doctor
      during the consultation for appropriate care, including a referral to a psychiatrist and / or
      addictologist if necessary.

      The duration of the inclusions will be 6 months and the number of patients to include is 250.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire in PrEP consultants</measure>
    <time_frame>1 year after the study start date</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Psychoactive Substance Use</condition>
  <condition>Mood Disorders</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To estimate the acceptability and the impact on the management of a systematic identification of the use of psychoactive substances and / or anxio-depressive disorders by self-questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>self-administered questionnaire</intervention_name>
    <description>The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject aged over 18,

          -  Subject seen in consultation in one of the centers of the study for a renewal of the
             Prep

          -  Subject having agreed to participate in the study

        Exclusion Criteria:

          -  Subject not speaking French / illiterate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Marc Jacquet, MD</last_name>
    <phone>+33662596948</phone>
    <email>jm-jacquet@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of Alès</name>
      <address>
        <city>Alès</city>
        <zip>30100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Bastide, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Jacquet, MD</last_name>
      <phone>+33662596948</phone>
      <email>jm-jacquet@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEGIDD</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béatrice Broche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UH NIMES</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Mauboussin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital of Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milagos Ferreyra, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Pre-exposure prophylaxis</keyword>
  <keyword>Recreational drugs</keyword>
  <keyword>Chemsex</keyword>
  <keyword>Mental disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

